Abstract Number: 2418 • ACR Convergence 2025
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…Abstract Number: 2402 • ACR Convergence 2025
High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Background/Purpose: Belimumab, a BAFF inhibitor, is an effective treatment for systemic lupus erythematosus (SLE), but biomarkers predicting treatment response remain elusive. We aimed to identify…Abstract Number: 2384 • ACR Convergence 2025
Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment…Abstract Number: 2215 • ACR Convergence 2025
Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Background/Purpose: Placenta-mediated adverse pregnancy outcomes (APO) are a huge concern in SLE. Recent efforts to understand APO include the establishment of the 2016 Amsterdam classification…Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…Abstract Number: 1853 • ACR Convergence 2025
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…Abstract Number: 1834 • ACR Convergence 2025
Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…Abstract Number: 1742 • ACR Convergence 2025
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Background/Purpose: Cognitive impairment is common in childhood-onset systemic lupus erythematosus (cSLE), particularly in domains like executive function and attention. However, attributing cognitive difficulties to brain…Abstract Number: 1686 • ACR Convergence 2025
The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Depression is reported to be common in SLE, but little is known about depressive symptoms among older adults with SLE. While the burden of…Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…Abstract Number: 1525 • ACR Convergence 2025
Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Background/Purpose: Emerging therapies such as CD19 CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 18 months. With rituximab,…Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1468 • ACR Convergence 2025
A HIPAA-Compliant LLM for Personalized Therapeutic Decision-Making in Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is the most significant driver of morbidity and mortality in patients with systemic lupus erythematosus (SLE). The ACR 2024 lupus nephritis…Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 181
- Next Page »